Bpifrance

DBV Technologies S.A. is a clinical-stage biopharmaceutical company focused on the research and development of epicutaneous immunotherapy products aimed at treating food allergies. The company’s lead candidate, Viaskin Peanut, has completed Phase III clinical trials for peanut allergies in children, adolescents, and adults. Additionally, DBV is developing Viaskin Milk, which is in Phase I/II trials for cow's milk protein allergy and related conditions, and Viaskin Egg, which is in pre-clinical stages for hen’s egg allergy. The company is also working on a booster vaccine for Bordetella pertussis, along with earlier-stage research programs targeting respiratory syncytial virus, Crohn’s disease, celiac disease, and type I diabetes. DBV Technologies collaborates with Nestlé Health Science to create MAG1C, a diagnostic patch test for non-IgE mediated cow's milk protein allergy in infants and toddlers. Founded in 2002, the company is headquartered in Montrouge, France.

Meiogenix SAS operates as a biotech company that develops breeding and genomic technologies. It offers SpiX technology, which modulates the process of homologous recombination in the genome by increasing its frequency in cold regions and PhoeniX, which is a non-GM method that induces meiotic recombination in hybrid diploid (or polyploid) yeast cells without the need to go through the entire process of meiosis. The company helps to develop new products to address global food and industrial challenges. The company was incorporated in 2010 and is based in Paris, France.

TreeFrog Therapeutics is a stem cell company based in Pessac, France, founded in 2018. It focuses on researching and producing scalable stem cell cultivation for cGMP cell therapy manufacturing. The company has developed C-Stem, a proprietary technology platform that offers an end-to-end 3D scalable solution, aimed at securing cell production and quality. This innovative approach is designed to expedite clinical development and facilitate market access for cell therapies. By addressing critical manufacturing challenges, TreeFrog Therapeutics aims to significantly reduce treatment costs, making advanced cell therapies more accessible to patients.

Biophytis is a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases. Their goal is to become a leader in the emerging field of aging science by delivering life-changing therapies to the growing number of patients in need that have limited or no treatment options. To accomplish this goal, they have assembled an experienced and skilled group of industry professionals, scientists, clinicians and key opinion leaders from leading industry and academic institutions from around the world.

Biophytis is a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases. Their goal is to become a leader in the emerging field of aging science by delivering life-changing therapies to the growing number of patients in need that have limited or no treatment options. To accomplish this goal, they have assembled an experienced and skilled group of industry professionals, scientists, clinicians and key opinion leaders from leading industry and academic institutions from around the world.

PILI Inc. researches and manufactures bio-fabricated colors by using microorganisms. The company designs enzymes and fermentation biotechnologies to efficiently transform sugar into renewable and long-lasting colors. PILI Inc. produces renewable dyes and pigments. The company was founded in 2012 and is based in Paris, France.

ERYtech Pharma, set up in Lyon (France) in 2004, specializes in the encapsulation of therapeutic molecules and enzymes in red blood cells. It has achieved a major breakthrough in the fields of cancer and enzyme therapy by significantly increasing the therapeutic index of the encapsulated molecule or enzyme.

VectivBio is a clinical-stage biotechnology company bringing transformational medicines to patients with serious rare diseases. They are committed to pursuing rare diseases with well-defined biology that can be targeted with best-in-disease therapies that have the potential to meaningfully transform and improve the lives of patients and their families, not just provide an incremental improvement or benefit over the standard-of-care. It was founded as a spinout from Therachon, a biotechnology company acquired by Pfizer for its program in achondroplasia. VectivBio was incorporated in 2019 and is based in Basel, Switzerland.

DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. Our revolutionary enzymatic technology powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results.

Honing Biosciences SAS, a bio-therapeutics company, develops and improves cell-based therapies to treat cancer and other chronic diseases. It offers molecular CellTuneTM technology that allows to develop new classes of tunable cell therapeutics to control the dynamic delivery of proteins in patients. The company offers therapies, such as CAR-T (chimeric antigen receptor T) cells therapy to kill cancer cells and Checkpoint inhibitors, a technology allowing to select small antibodies (nanobodies) based on proprietary scaffold, which they can deliver intracellularly. Its technology regulates protein expression at the cell surface or secretion of enzymes, cytokines, antibodies, and adapting the delivery of therapeutic proteins to clinical evolutions. Honing Biosciences SAS was incorporated in 2018 and is based in Paris, France.

Xenothera SAS, a biotechnology company, develops a platform with embedded technology that renovates immunological treatments. It develops new therapeutic modes in various domains from immunomodulation to infectious diseases. It addresses unmet medical needs with proprietary Glyco-Humanized Antibodies. The company’s therapeutic modes are based on animal genetics and mastery of immunology processes. It renovates passive immunotherapy by marketing a new generation of hyperimmune polyclonal sera. Xenothera SAS was incorporated in 2014 and is based in Nantes, France.

Ona Therapeutics is a biotech company that specializes in the discovery and development of therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. Founded in 2019 by Salvador Aznar-Benitah and Valerie Vanhooren, it was a spin-off from ICREA and Advanced Studies, and the IRB Institute for Research in Biomedicine.

Founded in 2009 in Lyon, France and located and member of LyonBiopôle cluster, Fab’entech is a biopharmaceutical company which develops and commercializes a range of innovative passive immunotherapeutic solutions based on specific polyclonal immunoglobulins [F(ab’)₂] in the field of emerging infectious diseases, as well as for certain drug intoxications.

VectivBio is a clinical-stage biotechnology company bringing transformational medicines to patients with serious rare diseases. They are committed to pursuing rare diseases with well-defined biology that can be targeted with best-in-disease therapies that have the potential to meaningfully transform and improve the lives of patients and their families, not just provide an incremental improvement or benefit over the standard-of-care. It was founded as a spinout from Therachon, a biotechnology company acquired by Pfizer for its program in achondroplasia. VectivBio was incorporated in 2019 and is based in Basel, Switzerland.

TreeFrog Therapeutics is a stem cell company based in Pessac, France, founded in 2018. It focuses on researching and producing scalable stem cell cultivation for cGMP cell therapy manufacturing. The company has developed C-Stem, a proprietary technology platform that offers an end-to-end 3D scalable solution, aimed at securing cell production and quality. This innovative approach is designed to expedite clinical development and facilitate market access for cell therapies. By addressing critical manufacturing challenges, TreeFrog Therapeutics aims to significantly reduce treatment costs, making advanced cell therapies more accessible to patients.

PILI Inc. researches and manufactures bio-fabricated colors by using microorganisms. The company designs enzymes and fermentation biotechnologies to efficiently transform sugar into renewable and long-lasting colors. PILI Inc. produces renewable dyes and pigments. The company was founded in 2012 and is based in Paris, France.

DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. Our revolutionary enzymatic technology powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results.

TreeFrog Therapeutics is a stem cell company based in Pessac, France, founded in 2018. It focuses on researching and producing scalable stem cell cultivation for cGMP cell therapy manufacturing. The company has developed C-Stem, a proprietary technology platform that offers an end-to-end 3D scalable solution, aimed at securing cell production and quality. This innovative approach is designed to expedite clinical development and facilitate market access for cell therapies. By addressing critical manufacturing challenges, TreeFrog Therapeutics aims to significantly reduce treatment costs, making advanced cell therapies more accessible to patients.

Ynsect is a biotech company based in Evry, France, founded in 2011. The company specializes in the design, construction, and operation of insect production and processing facilities aimed at producing sustainable feed for fish and poultry. Ynsect focuses on the bioconversion of organic resources through insects, transforming them into high-quality nutrients such as proteins and lipids for animal feed, as well as non-food applications like organic fertilizers and bioenergy. By leveraging insect nutrients and behaviors, Ynsect collaborates with clients to develop innovative products and services. The company is recognized for its expertise in large-scale insect farming and automated processing, making it a preferred partner among professionals in the agri-food sector, laboratories, investors, and public institutions.

In 2011, Alkion BioPharma has been created to revolutionize the secondary metabolims production for cancer therapies. Imperial Innovations, a team of Imperial College researchers and business professionals joined together to develop the technologies able to transform the non-GMO plants into a natural biorefinery. Quickly the technological platform received strong interests from the cosmetic community and the company signed research contracts to develop new disruptive cosmetic ingredients. Four years after inception, with a strong commercial pipeline, Alkion BioPharma has been acquired by Evonik Industries AG for cosmetic & food supplements applications. The new company Alkion BioInnovations was created in March 2017 in order to develop disruptive nutrition, non-cosmetic oil, and agrochemical solutions. The company owns exclusive rights on this applications.

DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. Our revolutionary enzymatic technology powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results.

ENYO Pharma SA is a clinical-stage biopharmaceutical company based in Lyon, France, focused on drug discovery and development for acute and chronic viral infections. Founded in 2014 by a group of scientists from the Infectiology Research Center, the company has established a unique platform to identify intracellular therapeutic targets and molecules, particularly for human pathogens. ENYO Pharma is developing treatments for significant viral infections, with ongoing programs targeting chronic hepatitis B and severe influenza. Its lead compound, EYP001, is designed to modulate FXR and reduce viral replication, while EYP002 is currently undergoing preclinical studies. The company aims to advance its pipeline into Phase II clinical trials and collaborates closely with research institutions to leverage innovative therapeutic strategies. ENYO Pharma is committed to addressing unmet medical needs in infectious and metabolic diseases, positioning itself as a leader in antiviral therapies.

PILI Inc. researches and manufactures bio-fabricated colors by using microorganisms. The company designs enzymes and fermentation biotechnologies to efficiently transform sugar into renewable and long-lasting colors. PILI Inc. produces renewable dyes and pigments. The company was founded in 2012 and is based in Paris, France.

DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. Our revolutionary enzymatic technology powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results.

TxCell S.A. is a biotechnology company based in Valbonne, France, specializing in cellular immunotherapies that leverage regulatory T cells (Tregs) to address severe chronic inflammatory diseases, autoimmunity, and transplantation challenges. The company develops innovative therapies using Tregs engineered with chimeric antigen receptors (CARs) for various conditions, including TX200, aimed at preventing graft rejection in solid organ transplants, and treatments for autoimmune diseases such as bullous pemphigoid and multiple sclerosis. TxCell is also advancing Ovasave, a therapy for refractory Crohn's disease, having completed an initial study with positive outcomes and planning further clinical trials. The company collaborates with prominent research institutions, including the Lübeck Institute of Experimental Dermatology and the University of British Columbia, to enhance its research and development efforts. TxCell operates as a subsidiary of Sangamo Therapeutics, Inc., continuing its focus on innovative immunotherapy solutions.

omicX decided to harness the exponentially growing collective intelligence in bioinformatics and to leverage it to exploit biological Big Data for novel applications in biotechnology, life science, medecine, agriculture and industry. Their fast-growing company has become a trusted leader and global reference in bioinformatics with users from world leading universities, medical institutions, pharmaceutical companies and the biotech industry.

TxCell S.A. is a biotechnology company based in Valbonne, France, specializing in cellular immunotherapies that leverage regulatory T cells (Tregs) to address severe chronic inflammatory diseases, autoimmunity, and transplantation challenges. The company develops innovative therapies using Tregs engineered with chimeric antigen receptors (CARs) for various conditions, including TX200, aimed at preventing graft rejection in solid organ transplants, and treatments for autoimmune diseases such as bullous pemphigoid and multiple sclerosis. TxCell is also advancing Ovasave, a therapy for refractory Crohn's disease, having completed an initial study with positive outcomes and planning further clinical trials. The company collaborates with prominent research institutions, including the Lübeck Institute of Experimental Dermatology and the University of British Columbia, to enhance its research and development efforts. TxCell operates as a subsidiary of Sangamo Therapeutics, Inc., continuing its focus on innovative immunotherapy solutions.

Ynsect is a biotech company based in Evry, France, founded in 2011. The company specializes in the design, construction, and operation of insect production and processing facilities aimed at producing sustainable feed for fish and poultry. Ynsect focuses on the bioconversion of organic resources through insects, transforming them into high-quality nutrients such as proteins and lipids for animal feed, as well as non-food applications like organic fertilizers and bioenergy. By leveraging insect nutrients and behaviors, Ynsect collaborates with clients to develop innovative products and services. The company is recognized for its expertise in large-scale insect farming and automated processing, making it a preferred partner among professionals in the agri-food sector, laboratories, investors, and public institutions.

In 2011, Alkion BioPharma has been created to revolutionize the secondary metabolims production for cancer therapies. Imperial Innovations, a team of Imperial College researchers and business professionals joined together to develop the technologies able to transform the non-GMO plants into a natural biorefinery. Quickly the technological platform received strong interests from the cosmetic community and the company signed research contracts to develop new disruptive cosmetic ingredients. Four years after inception, with a strong commercial pipeline, Alkion BioPharma has been acquired by Evonik Industries AG for cosmetic & food supplements applications. The new company Alkion BioInnovations was created in March 2017 in order to develop disruptive nutrition, non-cosmetic oil, and agrochemical solutions. The company owns exclusive rights on this applications.

Global Bioenergies SA is a French company established in 2008, specializing in the development of a biological process to convert renewable resources into isobutene, a crucial petrochemical building block. The company is unique in Europe for its innovative approach to producing hydrocarbons through fermentation, focusing not only on isobutene but also on other gaseous olefins such as propylene and butadiene. In addition to its production efforts, Global Bioenergies offers engineering services related to gas fermentation processes and is engaged in converting industrial emissions and gaseous carbon sources into valuable chemical compounds. The company operates an industrial pilot and is constructing a demonstration plant in Germany, while preparing for its first full-scale facility through a joint venture with Cristal Union called IBN-One.